Delfi Diagnostics' Advancements in Early Liver Cancer Detection: A Landmark Achievement in Liquid Biopsy Platforms

Feb 6, 2022

Great news from Open Field Capital investment, Delfi Diagnostics, which just published "..positive liver cancer detection data published in Cancer Discovery"

"The technology performed well even at the earliest stages of disease, and showed 88 percent sensitivity at 98 percent specificity in an average risk population."

Past performance is not indicative of future results. Any investment in any of the investments described entails a risk of loss and may not be suitable for all investors. The investments described are provided for informational purposes only. Open Field makes no representation that any of the investments described has ever been recommended by Open Field or that any of the investments described has, may or will be profitable.